2-Deoxyinosine
(Synonyms: 2'-脱氧肌苷) 目录号 : GC11581
A nucleoside form of hypoxanthine
Cas No.:890-38-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
2’-deoxyadenosine inhibits the growth of human colon-carcinoma cell lines and is found to be associated with purine nucleoside phosphorylase (PNP) deficiency.
In the absence of deoxycoformycin, 2’-deoxyadenosine is primarily deaminated to 2’-deoxyinosine and then converted into hypoxanthine. In the presence of the inhibitor, the deoxynucleoside, in addition to a phosphorylation process, undergoes phosphorolytic cleavage giving rise to adenine. The conversion of 2’-deoxyadenosine to adenine might represent a protective device, emerging when the activity of adenosine deaminase is reduced or inhibited. There is much evidence to indicate that the enzyme catalyzing this processs may be distinct from methylthioadenosine phosphorylase and S-adenosyl homocysteine hydrolase, which are the enzymes reported to be responsible for the formation of adenine from 28-deoxyadenosine in mammals[1].
References:
[1]. Bemi V, et al. Deoxyadenosine metabolism in a human colon-carcinoma cell line (LoVo) in relation to its cytotoxic effect in combination with deoxycoformycin. Int J Cancer. 1998 Mar 2;75(5):713-20.
|
Cell experiment: |
Various amounts of cells, ranging from 1,000 to 900,000, suspended in 3 mL of standard medium, are plated in 35-mm dishes and incubated in the absence (control) and in the presence of both 1 μM dCF and 0.1 mM dAdo, as indicated in each experiment. dCf was added to the standard medium 30 min before 2’-deoxyadenosine (dAdo). Furthermore, an incubation is performed in which 0.1 mM 2’-deoxyadenosine alone is added to the standard medium. After 4 days of incubation, the standard medium is withdrawn, then 0.5 mL of 0.025% trypsin containing 0.02% EDTA is added and kept for few minutes at 37°C. The cells are collected, diluted in an appropriate volume of standard medium, and counted[1]. |
|
References: [1]. Bemi V, et al. Deoxyadenosine metabolism in a human colon-carcinoma cell line (LoVo) in relation to its cytotoxic effect in combination with deoxycoformycin. Int J Cancer. 1998 Mar 2;75(5):713-20. |
|
| Cas No. | 890-38-0 | SDF | |
| 别名 | 2'-脱氧肌苷 | ||
| 化学名 | 9-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol | ||
| Canonical SMILES | OC[C@](O1)([H])[C@](O)([H])C[C@]1([H])N2C=NC3=C2N=CN=C3O | ||
| 分子式 | C10H12N4O4 | 分子量 | 252.23 |
| 溶解度 | ≥ 12.6mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9646 mL | 19.8232 mL | 39.6464 mL |
| 5 mM | 0.7929 mL | 3.9646 mL | 7.9293 mL |
| 10 mM | 0.3965 mL | 1.9823 mL | 3.9646 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet